SL
$77.25
+5.25
(+7.29%)
As of Oct 5, 2026, 3:36 PM EDT
Price history
Sol-Gel Technologies (SLGL) is trading up at $77.25 (+7.29%), as of the latest quote. It operates in the Health Care sector.
IPO: February 1, 2018 · $12.00 offering · NASDAQ · View IPO details →
Sol-Gel Technologies revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | $174.0K | $129.0K | $22.9M | $8.77M | $31.3M | $3.88M | $1.55M | $11.5M | $19.4M |
| Growth (year over year) | — | — | −25.9% | +17655.0% | −61.7% | +256.5% | −87.6% | −60.0% | +642.5% | +68.0% |
| Operating income | −$20.8M | −$31.6M | −$33.5M | −$25.9M | −$30.2M | $2.96M | −$16.2M | −$29.3M | −$12.0M | −$7.54M |
| Operating margin | — | −18179.9% | −25985.3% | −113.3% | −344.7% | 9.5% | −418.3% | −1885.8% | −104.1% | −38.9% |
| Net income | −$20.8M | −$31.6M | −$32.2M | −$24.6M | −$29.3M | $3.22M | −$14.9M | −$27.2M | −$10.6M | −$6.13M |
| Net margin | — | −18142.5% | −24963.6% | −107.4% | −333.9% | 10.3% | −384.3% | −1752.8% | −91.7% | −31.6% |
| EPS (diluted) | $330.00 | $502.00 | $180.00 | −$12.60 | −$13.00 | $1.40 | −$6.50 | −$10.01 | −$3.79 | −$2.19 |
| Balance sheet | ||||||||||
| Cash and equivalents | $7.00M | $5.02M | $5.33M | $9.41M | $7.12M | $20.1M | $12.4M | $7.51M | $19.5M | $11.0M |
| Total assets | $11.0M | $15.3M | $69.7M | $61.3M | $59.2M | $69.2M | $46.6M | $45.3M | $35.8M | $29.9M |
| Total liabilities | $42.3M | $68.0M | $5.77M | $8.84M | $8.31M | $13.6M | $4.42M | $6.64M | $7.00M | $7.11M |
| Shareholders' equity | −$31.3M | −$52.7M | $63.9M | $52.5M | $50.8M | $55.6M | $42.2M | $38.6M | $28.9M | $22.8M |
| Cash flow | ||||||||||
| Operating cash flow | −$18.5M | −$24.1M | −$23.5M | −$22.5M | −$25.2M | −$7.69M | −$9.48M | −$17.7M | −$13.9M | $322.0K |
| Capital expenditure | $385.0K | $1.93M | $1.05M | $597.0K | $449.0K | $143.0K | $171.0K | $134.0K | $2.00K | $47.0K |
| Free cash flow | −$18.9M | −$26.0M | −$24.5M | −$23.1M | −$25.7M | −$7.83M | −$9.65M | −$17.9M | −$13.9M | $275.0K |
RevenueNet income
| Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q1 FY24†Mar 2024 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $594.0K | — | $466.0K | $5.43M | — | $1.03M | $17.3M | — |
| Growth (year over year) | −83.1% | — | +55.3% | +814.6% | — | +121.2% | +217.7% | — |
| Operating income | −$6.53M | — | −$6.71M | $1.62M | — | −$9.07M | $11.2M | — |
| Operating margin | −1098.8% | — | −1440.1% | 29.9% | — | −879.6% | 65.1% | — |
| Net income | −$5.97M | — | −$6.34M | $1.98M | — | −$8.81M | $11.6M | — |
| Net margin | −1005.1% | — | −1361.4% | 36.4% | — | −854.3% | 67.3% | — |
| EPS (diluted) | −$2.20 | — | −$2.28 | $0.71 | — | −$3.16 | $4.17 | — |
| Balance sheet | ||||||||
| Cash and equivalents | $15.6M | $7.51M | — | $11.5M | $19.5M | — | $10.2M | $11.0M |
| Total assets | $55.1M | $45.3M | — | $42.0M | $35.8M | — | $39.3M | $29.9M |
| Total liabilities | $6.81M | $6.64M | — | $7.10M | $7.00M | — | $7.42M | $7.11M |
| Shareholders' equity | $48.3M | $38.6M | $32.7M | $34.9M | $28.9M | $20.2M | $31.9M | $22.8M |
From Sol-Gel Technologies's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Sol-Gel Technologies
- Headquarters
- Ness Ziona, Israel From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with SLGL
- SIBN Si Bone Inc
- SIGA Siga Technologies Inc
- SION Sionna Therapeutics Inc
- SLDB Solid Biosciences Inc
- SLNO Soleno Therapeutics Inc
- SLP Simulations Plus Inc
- SLS Sellas Life Sciences Group Inc
- SMMT Summit Therapeutics